Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
NCT07362017
·
clinicaltrials.gov ↗
PHASE3
Phase
NOT_YET_RECRUITING
Status
300
Enrollment
INDUSTRY
Sponsor class
Conditions
Moderate-to-severe Chronic Plaque Psoriasis
Interventions
DRUG:
Ponesimod
Sponsor
Vanda Pharmaceuticals